Cannabis stocks are having a moment few in the industry expected this early in 2026. The AdvisorShares Pure US Cannabis ETF (MSOS) has climbed to its highest levels of the year, with a one-year net asset value return of 103.7% through May 31 - more than triple the North American Marijuana Index's 36.9% gain and well ahead of the S&P 500's 29.8%. The catalyst is twofold: a Drug Enforcement Administration hearing later this month on broader marijuana rescheduling, and Trulieve Cannabis' arrival on the New York Stock Exchange under the ticker TRLV.
For operators watching from the retail floor rather than the trading floor, the rally is a reminder that capital markets and compliance policy move in the same direction more often than not. A senior exchange listing changes how a multi-state operator raises money, refinances debt, and pursues acquisitions - all of which eventually filter down to store-level decisions about staffing, inventory, and technology upgrades. Even in a state like Alaska, where the market is smaller and less crowded than California or Illinois, dispensary owners weighing new point-of-sale infrastructure are operating in the same regulatory current; finding the best point of sale for cannabis retail alaska operators can rely on matters just as much when capital gets cheaper and compliance software becomes easier to justify on a budget line.
Why the DEA Hearing Carries Weight
The administrative hearing set for June 29 will examine whether adult-use cannabis products, not just state-licensed medical marijuana, should move to Schedule III. That distinction matters enormously. In April, Acting Attorney General Todd Blanche moved medical marijuana products into Schedule III, a shift that eliminated tax penalties for licensed medical operators by allowing them to deduct ordinary business expenses - payroll, rent, interest - that Section 280E of the federal tax code had long disallowed. Extending that treatment to adult-use products would touch a far larger share of the industry's revenue base. President Trump's decision to formally nominate Blanche as permanent attorney general has only added to investor confidence that the rescheduling process will continue moving forward rather than stall.
What a Senior Listing Actually Changes
Trulieve's move to the NYSE required separating its medical cannabis operations from its adult-use business - a structural workaround that let the company qualify for a listing exchange still wary of federal illegality. CEO Kim Rivers called it a historic milestone, and in fairness, it is a meaningful one: a senior listing improves access to institutional capital, banking relationships, and analyst coverage that over-the-counter tickers rarely attract. Cresco Labs' $50 million revolving credit facility from Needham Bank, secured this week, is being framed by CEO Charlie Bachtell as a step toward the same goal - a non-dilutive financing tool that positions the company for a future uplisting rather than an immediate one.
That distinction between "positioned for" and "already there" matters. Uplisting speculation has driven much of the recent trading volume across MSOS holdings, but the mechanics of exchange qualification - audited financials, minimum share price thresholds, corporate governance standards - take time to satisfy even under favorable policy conditions.
Where the Upside Estimates Diverge
Not every MSOS holding is priced the same way relative to analyst targets. Verano carries the highest projected upside among the ETF's components at roughly 195%, followed by Jushi Holdings near 183% and Cresco Labs close to 99%. Trulieve, despite its size and its NYSE headline, shows a comparatively modest 27% upside to its price target, while Green Thumb Industries stands out among the larger holdings at 70%. Glass House is the outlier with a negative projected return, a reminder that sector-wide enthusiasm doesn't lift every operator's valuation equally.
- Trulieve (TCNNF): 30.2% weight, 27% upside
- Curaleaf (CURLF): 26.3% weight, 13% upside
- Green Thumb (GTBIF): 18.2% weight, 70% upside
- Verano (VRNO): 5% weight, 195% upside
Retail sentiment on platforms like Stocktwits has run extremely bullish for MSOS, Trulieve, and Green Thumb, with message volumes described as extremely high. Enthusiasm is not evidence, though, and operators and investors alike would do well to remember that federal rescheduling - even if it clears the June hearing - does not resolve state-level license caps, social equity licensing disputes, or the compliance burden of seed-to-sale tracking systems like METRC that dispensaries still have to manage daily regardless of what happens on Wall Street.
